GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avanos Medical Inc (NYSE:AVNS) » Definitions » Operating Income

Avanos Medical (Avanos Medical) Operating Income : $12.9 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Avanos Medical Operating Income?

Avanos Medical's Operating Income for the three months ended in Dec. 2023 was $11.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $12.9 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Avanos Medical's Operating Income for the three months ended in Dec. 2023 was $11.2 Mil. Avanos Medical's Revenue for the three months ended in Dec. 2023 was $173.3 Mil. Therefore, Avanos Medical's Operating Margin % for the quarter that ended in Dec. 2023 was 6.46%.

Avanos Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Avanos Medical's annualized ROC % for the quarter that ended in Dec. 2023 was 3.79%. Avanos Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 13.59%.


Avanos Medical Operating Income Historical Data

The historical data trend for Avanos Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avanos Medical Operating Income Chart

Avanos Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.70 -46.10 -39.00 35.50 4.20

Avanos Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.60 2.60 -2.10 1.20 11.20

Avanos Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avanos Medical  (NYSE:AVNS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Avanos Medical's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=44.8 * ( 1 - -23.6% )/( (1468.5 + 1455.2)/ 2 )
=55.3728/1461.85
=3.79 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Avanos Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=48.8/( ( (143.9 + max(258.5, 0)) + (144 + max(172, 0)) )/ 2 )
=48.8/( ( 402.4 + 316 )/ 2 )
=48.8/359.2
=13.59 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(138 + 156.6 + 115.7) - (149.3 + 0 + 2.5)
=258.5

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(128.7 + 163.2 + 93.3) - (149.5 + 0 + 63.7)
=172

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Avanos Medical's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=11.2/173.3
=6.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Avanos Medical Operating Income Related Terms

Thank you for viewing the detailed overview of Avanos Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Avanos Medical (Avanos Medical) Business Description

Traded in Other Exchanges
Address
5405 Windward Parkway, Suite 100 South, Alpharetta, GA, USA, 30004
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. The firm operates in one segment, medical devices, which primarily sells products related to pain management, IV Therapy, and respiratory and digestive health. The company divides its Medical Devices segment into two franchises: Pain Management and Chronic Care. Pain Management provides non-opioid products for acute and interventional pain, including cold and compression therapy. Chronic Care aims at addressing digestive and respiratory issues with feeding tubes and catheters. Avanos generates most of its revenue from its Chronic Care franchise and in North America.
Executives
Sudhakar Varshney officer: SVP, Global Supply Chain 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
John Joseph Hurley officer: Principal Accounting Officer 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Patrick J Oleary director 31515 BALLANTYNE CORP, C/O SPX CORP, CHARLOTTE NC 28277
Mojirade James officer: SVP, General Counsel 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Kerr Holbrook officer: SVP, GM Chronic Care 5405 WINDWARD PKWY, ALPHARETTA GA 30004
Michael Greiner officer: SVP - Chief Financial Officer C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421
David Edward Ball officer: SVP - Global Supply Chain AVANOS MEDICAL, INC., 5405 WINDWARD PKWY, ALPHARETTA GA 30004
William David Haydon officer: SVP, GM Pain Franchise 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Arjun Ranjan Sarker officer: Senior VP, International HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Joseph Fralin Woody director, officer: Chief Executive Officer 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA GA 30004
Steven E Voskuil officer: See Remarks 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John W Wesley director 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004
John Raymond Tushar officer: President, Global Franchises HALYARD HEALTH, INC., 5405 WINDWARD PARKWAY, ALPHARETTA GA 30004